Quantcast

Latest Daiichi Sankyo Stories

2011-07-19 07:00:00

TOKYO, July 19, 2011 /PRNewswire/ -- Building on its cardiovascular portfolio, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), is proud to announce the launch of LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN: edoxaban) in Japan. This announcement follows the first marketing approval for edoxaban 15 mg and 30 mg tablets by the Japanese Ministry of Health, Labor and Welfare in April 2011 (1), and marks the first time edoxaban is commercially available to...

2011-06-28 09:04:00

PARSIPPANY, N.J., June 28, 2011 /PRNewswire/ -- Daiichi Sankyo, Inc. (DSI) announced today that Danesha Dixon Smith has joined the company as its Vice President of Human Resources. "Hiring and developing results-driven employees who are passionate about their work and committed to patients -- our ultimate customers -- is a priority for our organization," said John P. Gargiulo, President and Chief Executive Officer of Daiichi Sankyo, Inc. "We believe every employee has a direct impact on...

2011-06-14 12:41:00

LISBON, Portugal, June 14, 2011 /PRNewswire/ -- Hovione announced today the international filing of its latest patent covering a new, highly efficient dry powder inhaler (DPI), XCaps. XCaps fills a void in the pulmonary inhalation market, as a device which combines high efficiency in powder dispersion with ease of use. Lung fractions in excess of 70% have been achieved, from a device which only requires two steps to inhalation and which only has two components plus a dust...

2011-05-23 07:00:00

PARSIPPANY, N.J., May 23, 2011 /PRNewswire/ -- Data evaluating the long-term efficacy and safety of olmesartan medoxomil, amlodipine besylate, plus hydrochlorothiazide (OM/AML + HCTZ) in patients with hypertension aged <65 years and greater than or equal to 65 years, showed that the triple therapy at Week 52 was both well-tolerated and effective in maintaining the blood pressure reductions seen in the pivotal study regardless of age.(1) The pre-specified subgroup analysis results,...

2011-05-20 07:30:00

EAST HANOVER, N.J. and PARSIPPANY, N.J., May 20, 2011 /PRNewswire/ -- During a 'Day of Science,' more than 30 middle school students from Newark Science Park High School experienced what it was like to be scientists for a day during a behind-the-scenes mentoring program hosted by Students 2 Science, Inc. (S2S). The "A Day in the Life of a Scientist" program is one of many integrated full-year science education programs offered by S2S that seeks to address the fact that American high school...

2011-05-17 07:03:00

SHIRLEY, N.Y. and PARSIPPANY, N.J., May 17, 2011 /PRNewswire/ -- Regency Therapeutics, a newly established division of Luitpold Pharmaceuticals, Inc., and its co-promotion partner Daiichi Sankyo, Inc., announced today that they have launched SPRIX® (ketorolac tromethamine) Nasal Spray and that it is now commercially available. SPRIX® was approved by the U.S. Food and Drug Administration (FDA) in May 2010 for the short-term (up to 5 days) management of...

2011-05-11 05:00:00

PARSIPPANY, N.J. and TOKYO, May 11, 2011 /PRNewswire/ -- Daiichi Sankyo announced that applications have been submitted for market approval for vemurafenib (PLX4032/RG7204) for the treatment of metastatic melanoma to the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Additionally, a pre-marketing application for approval for a companion diagnostic test has been submitted in the U.S.; the test also will be registered in Europe. Vemurafenib is an oral,...

2011-04-22 07:30:00

TOKYO, April 22, 2011 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo), announced today that the company has received its first marketing approval for LIXIANA® (JAN: Edoxaban Tosilate Hydrate, INN:edoxaban) 15 mg and 30 mg tablets, by the Ministry of Health, Labor and Welfare in Japan. Edoxaban, which is being developed solely by Daiichi Sankyo, is a once-daily, oral anticoagulant that specifically, reversibly and directly inhibits the enzyme,...

2011-04-20 08:05:00

PARSIPPANY, N.J., April 20, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Colesevelam HCI 625 mg tablets. Watson's Colesevelam HCI tablets are a generic version of Daiichi Sankyo, Inc.'s Welchol®. Daiichi Sankyo and Genzyme Corporation filed suit against Watson on...

2011-04-20 07:00:00

PARSIPPANY, N.J. and BETHESDA, Md., April 20, 2011 /PRNewswire/ -- The Sjogren's Syndrome Foundation (SSF), in partnership with Daiichi Sankyo Inc., today announced the launch of the Defy the Dry(TM) campaign, an educational initiative to ignite patient-physician dialogue about dryness symptoms. For those with Sjogren's syndrome today, it takes approximately seven years from the onset symptoms to an accurate diagnosis. Knowing this is too long to wait for a diagnosis, motivated patients...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related